MCL Clinical Trials

1230 trials from ClinicalTrials.gov. Recruiting trials shown first.

DALY II USA/ MB-CART2019.1 for DLBCL

NCT04792489·PHASE2·Miltenyi Biomedicine GmbH·248 enrolled

zamtocabtagene autoleucel (MB-CART2019.1)CyclophosphamideFludarabineBendamustine

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

NCT04830137·PHASE1·Nurix Therapeutics, Inc.·248 enrolled

CONFIRM: Magnetic Resonance Guided Radiation Therapy

NCT04368702·NA·Brigham and Women's Hospital·70 enrolled

Viewray MRIdian® Linac

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

NCT04566887·PHASE2·University Health Network, Toronto·105 enrolled

AcalabrutinibR-CHOP chemotherapy

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT04195633·PHASE2·Fred Hutchinson Cancer Center·60 enrolled

Allogeneic Hematopoietic Stem Cell TransplantationCyclophosphamideCyclosporineFilgrastimFludarabine+10 more

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT04484012·PHASE2·City of Hope Medical Center·36 enrolled

AcalabrutinibCD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

NCT04223765·PHASE1·UNC Lineberger Comprehensive Cancer Center·20 enrolled

CAR.k.28FludarabineCyclophosphamideBendamustine

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

NCT04329728·PHASE1 / PHASE2·AVM Biotechnology Inc·144 enrolled

Phase Ib Clinical Study of Keynatinib

NCT04807881·PHASE1·Medolution Ltd.·75 enrolled

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

NCT04545762·PHASE1·C. Babis Andreadis·36 enrolled

FludarabineCyclophosphamideanti-CD19 CAR-T cells

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

NCT04186520·PHASE1 / PHASE2·Medical College of Wisconsin·100 enrolled

8/12-Day Production of Car-T Cells8/12-Day Production of Cryopreserved Car-T Cells12-Day Production of Car-T Cells

Italian Observational Study on CAR-T Therapy for Lymphoma

NCT06339255·Paolo Corradini·5300 enrolled

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT04054167·PHASE2·M.D. Anderson Cancer Center·80 enrolled

Low Dose Radiation Therapy

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

NCT03824483·PHASE2·Memorial Sloan Kettering Cancer Center·230 enrolled

ZanubrutinibObinutuzumabVenetoclax

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

NCT03523975·PHASE1 / PHASE2·City of Hope Medical Center·28 enrolled

VenetoclaxLenalidomideRituximab

Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

NCT03616782·PHASE2·Ho Sup Lee·98 enrolled

REal World Data in LYmphoma and Survival in Adults

NCT03869619·Hospices Civils de Lyon·6000 enrolled

Real-life epidemiological platform of lymphoma in France

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

NCT03676504·PHASE1 / PHASE2·University Hospital Heidelberg·68 enrolled

CD19.CAR T CellsFludarabineCyclophosphamide

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

NCT03501576·Emory University·200 enrolled

Inactivated Influenza Vaccine

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT03314974·PHASE2·Masonic Cancer Center, University of Minnesota·300 enrolled

HSCT with TBI RegimenHSCT with Non-TBI Regimen

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

NCT03452774·Massive Bio, Inc.·50000 enrolled

Clinical Trial Matching

Long-term Follow-up Study of Patients Receiving CAR-T Cells

NCT03375619·Medical College of Wisconsin·500 enrolled

Long-Term Follow-Up of Participants who Received CAR-T cells

Liquid Biopsy in Mature B-cell Tumors

NCT03280394·Oncology Institute of Southern Switzerland·444 enrolled

Auto Stem Cell Transplant for Lymphoma Patients

NCT03125642·PHASE2·Masonic Cancer Center, University of Minnesota·150 enrolled

EtoposideBCNUAraCMelphalanPeripheral blood stem cell transplantation+3 more

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

NCT01962636·NA·Masonic Cancer Center, University of Minnesota·200 enrolled

FludarabineCyclophosphamideTotal Body IrradiationCyclosporine AMycophenylate mofetil+1 more

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

NCT02858258·PHASE3·Prof. Dr. M. Dreyling (co-chairman)·870 enrolled

R-CHOP/R-DHAPIbrutinib (Induction)ASCT conditioningIbrutinib (Maintenance)

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686·PHASE3·Janssen Research & Development, LLC·700 enrolled

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

NCT00935090·Barbara Ann Karmanos Cancer Institute

3'-deoxy-3'-[18F]fluorothymidine

Registry of Older Patients With Cancer

NCT01137825·UNC Lineberger Comprehensive Cancer Center·3000 enrolled

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

NCT01137643·UNC Lineberger Comprehensive Cancer Center·15000 enrolled

biologic sample preservation procedurecytology specimen collection procedure

← PreviousPage 4 of 41Next →